Swiss drug manufacturers Novartis have developed a drug for advanced lung cancer. European health regulators have recommended approval of the drug, which is intended to treat patients with a specific genetic mutation.
A new class medicines Zykadia, or ceritinib known as ALK (Anaplastic lymphoma kinase) inhibitors was approved last year in the United States.
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
Advertisement
It is designed for use in non-small cell lung cancer patients who have previously been treated with another ALK inhibitor, Pfizer's Xalkori.
The drug is targeted for a specific mutation of the ALK protein found mainly in 2 - 7 percent of non-small cell lung cancer patients.
Source: Medindia
Source: Medindia
First-in-Class Drugs in Pipeline for Non-Small Cell Lung Cancer
Newer drugs are in the pipeline for the treatment of Non-Small Cell Lung Cancer (NSCLC) which will provide targeted treatment and hopefully improve the prognosis of patients with lung cancer.
Advertisement
 Trained Sniffer Dogs Help to Screen Lung CancerScientists in Germany have discovered that sniffer dogs are very reliable when it comes to detecting lung cancer. | Advertisement
|
Advertisement
